Bio-Rad Laboratories (BIO-B) Stock: Why It Moved
Updated Oct 16, 2026, 4:00 PM ET · closing price
- Closed at $364.15, +0.00% vs the prior close of $364.15.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
BIO-B ends flat (+0.0%) to $364.15, 20 down days in a row. Closed at $364.15, +0.00% vs the prior close of $364.15. Day range $364.15–$364.15, opened at $364.15.
BIO-B daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 16, 2026 — BIO-B ends flat (+0.0%) to $364.15, 20 down days in a row
- Closed at $364.15, +0.00% vs the prior close of $364.15. Day range $364.15–$364.15, opened at $364.15.
- Price is +1.2% vs its 50-day average ($359.97) and +18.2% vs its 200-day average ($308.06).
- 52-week range $244.54–$365.08; today's close sits at 99% of that range, 0.3% below the 52-week high.
- That makes 20 straight losses.
Oct 15, 2026 — BIO-B ends flat (+0.0%) to $364.15, 20 down days in a row
- Closed at $364.15, +0.00% vs the prior close of $364.15. Day range $364.15–$364.15, opened at $364.15.
- Price is +1.3% vs its 50-day average ($359.43) and +18.3% vs its 200-day average ($307.79).
- 52-week range $244.54–$365.08; today's close sits at 99% of that range, 0.3% below the 52-week high.
- That makes 20 straight losses.
Oct 14, 2026 — BIO-B ends flat (-0.3%) to $364.15, a 1-month low on 100.0x normal volume
- Closed at $364.15, -0.25% vs the prior close of $365.08. Day range $364.15–$364.21, opened at $364.21.
- Volume was 200 shares, 100.0x its 50-day average of 2 — unusually heavy trading.
- Price is +1.5% vs its 50-day average ($358.88) and +18.4% vs its 200-day average ($307.53).
- 52-week range $244.54–$365.08; today's close sits at 99% of that range, 0.3% below the 52-week high.
- That makes 20 straight losses.
Oct 13, 2026 — BIO-B ends flat (+0.0%) to $365.08, 20 down days in a row
- Closed at $365.08, +0.00% vs the prior close of $365.08. Day range $365.08–$365.08, opened at $365.08.
- Price is +1.9% vs its 50-day average ($358.34) and +18.8% vs its 200-day average ($307.26).
- 52-week range $244.54–$365.08; today's close sits at 100% of that range, at a new 52-week high.
- That makes 20 straight losses.
Oct 12, 2026 — BIO-B ends flat (+0.0%) to $365.08, 20 down days in a row
- Closed at $365.08, +0.00% vs the prior close of $365.08. Day range $365.08–$365.08, opened at $365.08.
- Price is +2.0% vs its 50-day average ($357.78) and +18.9% vs its 200-day average ($306.99).
- 52-week range $244.54–$365.08; today's close sits at 100% of that range, at a new 52-week high.
- That makes 20 straight losses.
Oct 9, 2026 — BIO-B ends flat (+0.0%) to $365.08, 20 down days in a row
- Closed at $365.08, +0.00% vs the prior close of $365.08. Day range $365.08–$365.08, opened at $365.08.
- Price is +2.4% vs its 50-day average ($356.66) and +19.0% vs its 200-day average ($306.71).
- 52-week range $244.54–$365.08; today's close sits at 100% of that range, at a new 52-week high.
- That makes 20 straight losses.
Oct 8, 2026 — BIO-B ends flat (+0.0%) to $365.08, 20 down days in a row
- Closed at $365.08, +0.00% vs the prior close of $365.08. Day range $365.08–$365.08, opened at $365.08.
- Price is +2.7% vs its 50-day average ($355.55) and +19.1% vs its 200-day average ($306.44).
- 52-week range $244.54–$365.08; today's close sits at 100% of that range, at a new 52-week high.
- That makes 20 straight losses.
Oct 7, 2026 — BIO-B ends flat (+0.0%) to $365.08, 20 down days in a row
- Closed at $365.08, +0.00% vs the prior close of $365.08. Day range $365.08–$365.08, opened at $365.08.
- Price is +3.0% vs its 50-day average ($354.44) and +19.2% vs its 200-day average ($306.17).
- 52-week range $244.54–$365.08; today's close sits at 100% of that range, at a new 52-week high.
- That makes 20 straight losses.
Oct 6, 2026 — BIO-B ends flat (+0.0%) to $365.08, 20 down days in a row
- Closed at $365.08, +0.00% vs the prior close of $365.08. Day range $365.08–$365.08, opened at $365.08.
- Price is +3.3% vs its 50-day average ($353.32) and +19.3% vs its 200-day average ($305.90).
- 52-week range $244.54–$365.08; today's close sits at 100% of that range, at a new 52-week high.
- That makes 20 straight losses.
Oct 5, 2026 — BIO-B ends flat (+0.0%) to $365.08, 20 down days in a row
- Closed at $365.08, +0.00% vs the prior close of $365.08. Day range $365.08–$365.08, opened at $365.08.
- Price is +3.7% vs its 50-day average ($352.21) and +19.5% vs its 200-day average ($305.63).
- 52-week range $244.54–$365.08; today's close sits at 100% of that range, at a new 52-week high.
- That makes 20 straight losses.
Oct 2, 2026 — BIO-B ends flat (+0.0%) to $365.08, 20 down days in a row
- Closed at $365.08, +0.00% vs the prior close of $365.08. Day range $365.08–$365.08, opened at $365.08.
- Price is +4.0% vs its 50-day average ($351.09) and +19.6% vs its 200-day average ($305.35).
- 52-week range $244.54–$365.08; today's close sits at 100% of that range, at a new 52-week high.
- That makes 20 straight losses.
BIO-B bull case vs bear case (from the data)
- Price is +1.2% vs its 50-day average — short-term trend is up.
- Price is +18.2% vs its 200-day average — above the long-term trend line.
- Annual revenue grew 0.7% in the latest fiscal year (SEC XBRL).
- Latest fiscal-year net income: profit of $759.90M.
- Insider selling outweighs buying: 8 sales vs 0 open-market buys among the 8 most recent reported insider trades (Form 4, last 12 months).
- Thin trading (under $2M a day on average) can mean wide bid/ask spreads.
BIO-B latest news & SEC filings
Every SEC filing by or about BIO-B in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 4, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $651.00M (prior year $651.60M) (-0.1% vs Jun 30, 2025)
- Net income: $371.40M (prior year $317.80M) (+16.9% vs Jun 30, 2025)
- Diluted EPS: $13.85 (prior year $11.67) (+18.7% vs Jun 30, 2025)
Aug 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 2.05 — Costs tied to exiting activities / restructuring.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade BIO-B
- Last results release: Aug 4, 2026 (8-K Item 2.02). Previous ones: Apr 30, 2026, Feb 12, 2026, Oct 29, 2025. Based on that rhythm, the next report is likely around Nov 3, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 0.01% (largest 0.3%). That is a relatively calm stock.
- Liquidity: about 10 shares (≈$3.64K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $364.15 vs a range of $244.54–$365.08 (99% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 8 sales; latest: Eva Anette Engelhardt sold 550 shares on May 11, 2026.
- Latest filings: 10-Q Aug 4, 2026; 8-K Aug 4, 2026; 10-Q Apr 30, 2026.
- Listing: NYSE · industry: Laboratory Analytical Instruments.
BIO-B market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 364.15 | 364.15 | 364.15 | 364.15 | 0 |
| Oct 15, 2026 | 364.15 | 364.15 | 364.15 | 364.15 | 0 |
| Oct 14, 2026 | 364.21 | 364.21 | 364.15 | 364.15 | 200 |
| Oct 13, 2026 | 365.08 | 365.08 | 365.08 | 365.08 | 0 |
| Oct 12, 2026 | 365.08 | 365.08 | 365.08 | 365.08 | 0 |
| Oct 9, 2026 | 365.08 | 365.08 | 365.08 | 365.08 | 0 |
| Oct 8, 2026 | 365.08 | 365.08 | 365.08 | 365.08 | 0 |
| Oct 7, 2026 | 365.08 | 365.08 | 365.08 | 365.08 | 0 |
| Oct 6, 2026 | 365.08 | 365.08 | 365.08 | 365.08 | 0 |
| Oct 5, 2026 | 365.08 | 365.08 | 365.08 | 365.08 | 0 |
| Oct 2, 2026 | 365.08 | 365.08 | 365.08 | 365.08 | 0 |
| Oct 1, 2026 | 365.08 | 365.08 | 365.08 | 365.08 | 0 |
| Sep 30, 2026 | 365.08 | 365.08 | 365.08 | 365.08 | 0 |
| Sep 29, 2026 | 365.08 | 365.08 | 365.08 | 365.08 | 0 |
| Sep 28, 2026 | 365.08 | 365.08 | 365.08 | 365.08 | 0 |
| Sep 25, 2026 | 365.08 | 365.08 | 365.08 | 365.08 | 0 |
| Sep 24, 2026 | 365.08 | 365.08 | 365.08 | 365.08 | 0 |
| Sep 23, 2026 | 365.08 | 365.08 | 365.08 | 365.08 | 0 |
| Sep 22, 2026 | 365.08 | 365.08 | 365.08 | 365.08 | 0 |
| Sep 21, 2026 | 365.08 | 365.08 | 365.08 | 365.08 | 0 |
About Bio-Rad Laboratories
Bio-Rad Laboratories (BIO-B) is listed on the NYSE and classified by the SEC under “Laboratory Analytical Instruments”. Its business address is in HERCULES, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 12208.
BIO-B board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Schwartz Allison | Director | Sep 9, 2026 |
| Jeffrey L Edwards | Director | Apr 23, 2026 |
| Greg K Hinckley | Director | Apr 23, 2026 |
| Melinda Litherland Pei | Director | Apr 23, 2026 |
| Arnold A Pinkston | Director | Apr 23, 2026 |
| Norman D Schwartz | Chairman & CEO | Sep 9, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| James Barry | EVP, President, LSG | Sep 9, 2026 |
| Jonathan P. Divincenzo | President & COO | Sep 9, 2026 |
| Eva Anette Engelhardt | EVP, President, CDG | Sep 9, 2026 |
| Courtney C Enloe | EVP, General Counsel & Sec | Sep 9, 2026 |
| Sedat Evran | EVP, Global Supply Chain | Sep 9, 2026 |
| Roop Kalyan Lakkaraju | EVP, Chief Financial Officer | Sep 9, 2026 |
| Rajat Mehta | EVP, GBL Commercial Operations | Sep 9, 2026 |
| Norman D Schwartz | Chairman & CEO | Sep 9, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 11, 2026 | Eva Anette Engelhardt | Sale | 550 | $246.54 |
| May 11, 2026 | Eva Anette Engelhardt | Sale | 550 | $246.54 |
| May 11, 2026 | Eva Anette Engelhardt | Sale | 550 | $246.54 |
| May 11, 2026 | Eva Anette Engelhardt | Sale | 550 | $246.54 |
| Nov 6, 2025 | James Barry | Sale | 700 | $306.18 |
| Nov 6, 2025 | James Barry | Sale | 700 | $306.18 |
| Nov 6, 2025 | James Barry | Sale | 700 | $306.18 |
| Nov 6, 2025 | James Barry | Sale | 700 | $306.18 |
BIO-B financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $2.58B | $759.90M | 27.85 | $532.20M |
| Dec 31, 2024 | $2.57B | $-1.84B | -65.36 | $455.20M |
| Dec 31, 2023 | $2.67B | $-637.30M | -21.82 | $374.90M |
| Dec 31, 2022 | $2.80B | $-3.63B | -121.79 | $194.40M |
| Dec 31, 2021 | $2.92B | $4.25B | 140.83 | $669.46M |
Latest balance sheet: total assets $10.25B, total liabilities $3.08B, cash $517.00M (as of Jun 30, 2026).
BIO-B earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 4, 2026 | 8-K Item 2.02 (results) | $337.00 |
| Apr 30, 2026 | 8-K Item 2.02 (results) | $299.45 |
| Feb 12, 2026 | 8-K Item 2.02 (results) | $295.05 |
| Oct 29, 2025 | 8-K Item 2.02 (results) | $321.12 |
| Jul 31, 2025 | 8-K Item 2.02 (results) | $247.05 |
| May 1, 2025 | 8-K Item 2.02 (results) | $234.41 |
| Feb 13, 2025 | 8-K Item 2.02 (results) | $312.05 |
| Oct 30, 2024 | 8-K Item 2.02 (results) | $334.85 |
| Aug 1, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Feb 15, 2024 | 8-K Item 2.02 (results) | — |
| Oct 26, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Laboratory Analytical Instruments
Illumina (ILMN)Agilent Technologies (A)Waters (WAT)10x Genomics (TXG)Mettler Toledo International Inc/ (MTD)Revvity (RVTY)Avantor (AVTR)Bruker (BRKR)Pacific Biosciences Of California (PACB)Alamar Biosciences (ALMR)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on BIO-B
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.